Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | HTT | P42858 | 4/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.75 |
| ▸ | PKM | P14618 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703229 | 0.90 | LMNA (0.80) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL12027 | 0.90 | LMNA (0.80) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL11672 | 0.89 | ALDH1A1 (0.75) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL12129 | 0.87 | ALDH1A1 (0.69) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL28023890 | 0.87 | LMNA (0.81) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL12178 | 0.87 | LMNA (0.70) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL11636 | 0.86 | LMNA (0.66) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL20976510 | 0.86 | LMNA (0.66) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL1980459 | 0.84 | LMNA (0.64) | LMNAALOX15USP2ALDH1A1HTT | |
| SCHEMBL12011 | 0.84 | LMNA (0.68) | LMNAALOX15USP2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-3561077-B1 | METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER LAB (FR) | 2022-12-21 | — | — | EP | disclosed |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2020-09-10 | — | — | US | disclosed |
| US-10711314-B2 | Methods for diagnosing IDH-mutant cell proliferation disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10610125-B2 | Methods and compositions for cell-proliferation-related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3561077-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190276894-A1 | METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2019-09-12 | — | — | US | disclosed |
| EP-2406389-B1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9982309-B2 | Method for treating cell proliferation related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2491145-B1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20150240286-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140187435-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130288284-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-10-31 | — | — | US | disclosed |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-07-18 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2012-05-17 | — | — | US | disclosed |
| WO-2011072174-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011050210-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010105243-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711314-B2 | Methods for diagnosing IDH-mutant cell proliferation disorders | MKI67, IDH1, IDH3A | LMNA 3404/4885ALOX15 3510/4885USP2 604/4885 |
| US-10610125-B2 | Methods and compositions for cell-proliferation-related disorders | MKI67, BRCA1, CLN6 | LMNA 708/4885ALOX15 3069/4885USP2 1184/4885 |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | LMNA 708/4885ALOX15 3069/4885USP2 1184/4885 |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | LMNA 708/4885ALOX15 3069/4885USP2 1184/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | LMNA 708/4885ALOX15 3069/4885USP2 1184/4885 |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, MKI67 | LMNA 1485/4885ALOX15 4635/4885USP2 980/4885 |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | LMNA 1011/4885ALOX15 1580/4885USP2 3550/4885 |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | LMNA 708/4885ALOX15 3069/4885USP2 1184/4885 |
| US-20190276894-A1 | METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS | IDH2, IDH1, IDH3A | LMNA 1683/4885ALOX15 3861/4885USP2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.